Clinical Trials Logo

Clinical Trial Summary

The new outbreak of the SARS-CoV-2 coronavirus is causing an important pandemic affecting a large number of people all-over the world. Vitamin D is a hormone precursor produced by our own body with the help of sunlight which has an important role on adaptive immunity and cellular differentiation, maturation and proliferation of several immune cells. Reduced levels of vitamin D in calves were positioned as the main cause of bovine coronavirus infection in the past. Therefore, it seems plausible that the use of vitamin D as a nutritional ergogenic aid could be a potential intervention to fight against COVID-19 infected patients which remain asymptomatic or which have non-severe and severe symptoms. This study aims to investigate whether the use of vitamin D as an immune modulator agent induces significant improvements of health status and outcomes in non-severe symptomatic patients infected with COVID-19 as well as preventing COVID-19 health deterioration. We hypothesize that vitamin D will significantly improve hard endpoints related to COVID-19 deleterious consequences compared with a usual care control group.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04334005
Study type Interventional
Source Universidad de Granada
Contact Manuel J Castillo, MD, PhD
Phone +34 649440850
Email mcgarzon@ugr.es
Status Not yet recruiting
Phase N/A
Start date April 10, 2020
Completion date June 30, 2020